Mariana Oncology is a fully integrated radiopharmaceutical company focused on targeted peptide-based therapies composed of rationally designed conjugates that deliver alpha or beta-emitting radionuclide payloads. The company engineers molecules intended to penetrate solid tumors more effectively than antibodies and to deliver high radiation doses without the side effects associated with chemotherapy and toxin-based strategies. Its lead candidate, MC-339, is a peptidic small molecule engineered to carry an actinium payload for targeted therapy of small cell lung cancer, and Mariana anticipates MC-339 will enter the clinic in 2024. The company is transitioning into a clinical-stage organization and plans to support early clinical development using its own GMP radiopharmaceutical manufacturing. Mariana describes a diversified pipeline of novel molecules aimed at broader indications beyond prostate cancer. Financially, Mariana closed an oversubscribed $175 million Series B, with proceeds designated to advance the pipeline and initial development of MC-339.

Total raised

$175M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2023